If you used compounded semaglutide for weight management over the past few years, you are not alone. Millions of Americans turned to compounding pharmacies when brand-name Ozempic and Wegovy were virtually impossible to find. But a rapid series of regulatory actions between late 2024 and mid-2025 fundamentally changed the compounded semaglutide market.
Whether you are mid-treatment and scrambling for options, or you have been researching semaglutide and just learned that the compounded route has narrowed considerably, this article breaks down the full timeline, the current legal reality, and every alternative worth considering in 2026.
What Is Compounded Semaglutide?
To understand the current situation, it helps to first understand what compounding actually means and why compounded semaglutide became so popular.
Brand-Name Semaglutide: The Basics
Semaglutide is a GLP-1 receptor agonist, a class of medications that mimics a natural hormone called glucagon-like peptide-1. Your body produces GLP-1 after eating, and it performs several important functions: it signals the pancreas to release insulin, tells the brain’s appetite centers (specifically the hypothalamus) that you are full, and slows the rate at which food leaves your stomach (Gasbjerg et al., 2024).
Think of GLP-1 as your body’s built-in “meal satisfaction” signal. Semaglutide is essentially a longer-lasting, more potent version of that signal. While natural GLP-1 breaks down in minutes, semaglutide is engineered to last about a week, which is why it works as a once-weekly injection.
The FDA has approved semaglutide under two brand names:
- Ozempic (semaglutide injection, 0.5 mg, 1 mg, 2 mg) — approved for type 2 diabetes management
- Wegovy (semaglutide injection, 2.4 mg) — approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition
Both are manufactured exclusively by Novo Nordisk.
What “Compounded” Means
Compounding is the practice of a licensed pharmacy creating a customized medication for an individual patient, typically when a commercially available product does not meet that patient’s needs. For example, a compounding pharmacy might prepare a medication in a different dosage form, remove an allergen, or adjust the concentration.
There are two types of compounding facilities recognized under federal law:
- 503A pharmacies — Traditional compounding pharmacies that prepare medications based on individual prescriptions from a licensed prescriber. They operate under state pharmacy board oversight.
- 503B outsourcing facilities — Larger-scale compounding operations that voluntarily register with the FDA and can produce compounded drugs without patient-specific prescriptions. They face more rigorous federal oversight, including FDA inspections.
Under normal circumstances, compounding pharmacies generally cannot produce medications that are “essentially a copy” of a commercially available FDA-approved drug. However, there is an important exception: when the FDA places a drug on its official shortage list, compounders gain temporary legal authority to produce copies to help meet patient demand.
Why Compounded Semaglutide Became So Popular
When Ozempic and Wegovy experienced severe supply shortages beginning in 2022, compounding pharmacies stepped in to fill the gap. Compounded semaglutide became popular for several reasons:
- Availability — It was often the only way patients could access semaglutide during the shortage
- Cost — Compounded versions typically cost $200–$500 per month, a fraction of the $1,000+ retail price of the brand-name drugs
- Dose flexibility — Compounders could prepare non-standard doses for patients who needed gradual titration
- Telehealth access — Many telehealth platforms partnered with compounding pharmacies, making the process convenient
At the peak of the shortage, some estimates suggest that compounded semaglutide accounted for a significant share of all semaglutide prescriptions in the United States.
The FDA Shortage and Compounding Timeline
Understanding the timeline is critical to understanding where things stand today. Here is how events unfolded:
2022: The Shortage Begins
The FDA first added semaglutide injection products to its official drug shortage list in 2022. Demand for Ozempic and Wegovy surged far beyond what Novo Nordisk could manufacture, driven by widespread media coverage of the drugs’ weight loss effects and a rapid increase in off-label prescribing.
With semaglutide on the shortage list, both 503A and 503B compounding facilities gained the legal authority to produce compounded versions, provided they followed applicable regulations.
2023–2024: The Compounding Boom
During this period, the compounded semaglutide market exploded. Hundreds of telehealth companies and compounding pharmacies began offering compounded semaglutide, often at prices dramatically lower than the brand-name products. The market grew into a multi-billion-dollar industry practically overnight.
However, concerns about quality and safety began emerging. The FDA received reports of adverse events linked to compounded products, including dosing errors where patients accidentally administered 5 to 20 times their intended dose because of confusing concentration labeling.
February 2025: The Shortage Officially Ends
On February 21, 2025, the FDA updated its drug shortage database and declared that the shortage of all doses of injectable semaglutide (both Ozempic and Wegovy) had been resolved. Novo Nordisk’s massive manufacturing expansion—including billions of dollars in new facilities across the United States, Denmark, Ireland, and other countries—had finally brought supply in line with demand.
This single announcement changed everything for the compounding industry. Once a drug is no longer on the shortage list, the legal basis for compounding “essentially a copy” of that drug disappears.
Spring 2025: Enforcement Deadlines Hit
The FDA established specific wind-down periods:
- 503A pharmacies received a 60-day grace period (until approximately April 22, 2025) to stop compounding products that were essentially copies of FDA-approved semaglutide
- 503B outsourcing facilities received a 90-day grace period (until approximately May 22, 2025) to do the same
After these deadlines, any compounding pharmacy producing a product that was “essentially a copy” of Ozempic or Wegovy was in violation of federal law.
September 2025: The Warning Letter Wave
In September 2025, the FDA sent warning letters to more than 50 compounders and manufacturers of GLP-1 drugs. The letters targeted several issues:
- False marketing claims — Companies claiming their compounded products were “generic” versions or had the “same active ingredient” with equivalent safety and efficacy
- Manufacturing violations — Facilities where sterility and potency testing failures were documented
- Misleading advertising — Marketing that implied compounded products were interchangeable with FDA-approved drugs
State attorneys general also began enforcement actions, using consumer protection laws to go after companies operating outside the bounds of federal drug law.
Early 2026: Ongoing Enforcement and Oral Semaglutide Launch
Enforcement actions have continued into 2026, with the FDA and Department of Justice pursuing cases against non-compliant compounders. Meanwhile, Novo Nordisk launched oral semaglutide (Wegovy tablets, 25 mg once daily) in the United States in early January 2026, further expanding legitimate access to the medication.
Current Legal Status in 2026
As of March 2026, here is where things stand legally:
What Is NOT Allowed
- Compounding pharmacies cannot produce semaglutide products that are “essentially a copy” of Ozempic or Wegovy, since the shortage has been resolved
- Companies cannot market compounded semaglutide as equivalent to, a generic version of, or interchangeable with FDA-approved products
- Compounders cannot use semaglutide salt forms (such as semaglutide sodium or semaglutide acetate) and market them as equivalent to the approved base form
What IS Still Allowed (In Limited Circumstances)
The FDA’s enforcement actions did not create a blanket prohibition on all semaglutide compounding. In narrow circumstances, compounding may still be permissible:
- Patient-specific medical need — A 503A pharmacy may compound semaglutide for an individual patient when a licensed prescriber determines that the commercially available product does not meet that specific patient’s medical needs
- Non-copy formulations — Compounders may produce semaglutide products that are genuinely different from the commercial versions and meet a documented patient-specific need
In practice, however, the broad availability of compounded semaglutide that existed during the shortage is gone.
State-Level Variation
Some states have enacted their own regulations regarding compounded GLP-1 drugs, and enforcement can vary by jurisdiction. However, federal law provides the baseline, and the FDA has made clear its intent to enforce against non-compliant compounders regardless of state-level permissiveness.
What Are Your Options Now?
If you were using compounded semaglutide or are interested in semaglutide for weight management, here are the realistic options available in 2026:
1. Brand-Name Prescriptions (Ozempic or Wegovy)
With the shortage resolved, Ozempic and Wegovy are now widely available at pharmacies nationwide. These are the only FDA-approved semaglutide products.
How to access them:
- Schedule an appointment with your primary care physician, endocrinologist, or obesity medicine specialist
- Discuss whether semaglutide is appropriate for your situation
- If prescribed, use the manufacturer’s savings programs to reduce costs
Key consideration: Insurance coverage remains inconsistent. Many plans cover Ozempic for type 2 diabetes but not for weight management alone. Wegovy coverage for obesity varies significantly by insurer and plan.
2. Oral Semaglutide (Wegovy Tablets)
One of the biggest developments in 2026 is the FDA approval and launch of oral semaglutide for weight management. The Wegovy tablet (25 mg, taken once daily) provides a needle-free alternative for patients who prefer not to inject.
Key consideration: The oral formulation must be taken on an empty stomach with a small amount of water, and you need to wait at least 30 minutes before eating or taking other medications. Adherence to these instructions is important for proper absorption.
3. Telehealth Weight Management Providers
Many telehealth platforms now prescribe brand-name Ozempic or Wegovy directly, rather than compounded versions. Reputable platforms typically employ licensed physicians, require a medical evaluation before prescribing, prescribe only FDA-approved medications, and provide ongoing monitoring.
Key consideration: Be cautious of platforms that still advertise “compounded semaglutide” at suspiciously low prices. If a deal seems too good to be true, it probably is.
4. Tirzepatide (Mounjaro/Zepbound)
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown impressive results in clinical trials. It works on two gut hormone pathways instead of one, which may provide additional benefits for some patients.
- Mounjaro is FDA-approved for type 2 diabetes
- Zepbound is FDA-approved for chronic weight management
Research from the SURMOUNT trials has demonstrated significant weight reduction in study participants, and some head-to-head comparisons suggest tirzepatide may produce greater weight loss than semaglutide in certain populations.
Learn more: Tirzepatide for Weight Loss: Dosage, Results & What to Know
5. Other GLP-1 and Related Medications
The GLP-1 medication landscape continues to expand. Other options that may be available or in late-stage development include:
- Liraglutide (Saxenda) — An older GLP-1 receptor agonist approved for weight management, administered as a daily injection
- Survodutide — A dual glucagon/GLP-1 receptor agonist in clinical trials
- Retatrutide — A triple-hormone receptor agonist (GIP, GLP-1, and glucagon) in Phase 3 trials showing promising early results
- Orforglipron — An oral, non-peptide GLP-1 receptor agonist in late-stage trials
6. Lifestyle-Based Approaches
For individuals who cannot access or afford GLP-1 medications, evidence-based lifestyle interventions remain foundational for weight management:
- Structured nutrition plans — Working with a registered dietitian to create sustainable eating patterns
- Regular physical activity — Both aerobic exercise and resistance training contribute to weight management and metabolic health
- Behavioral therapy — Cognitive behavioral therapy and other behavioral approaches can address the psychological components of eating behavior
- Sleep optimization — Research increasingly links poor sleep quality and insufficient sleep duration with weight gain
- Medical supervision — Working with a physician who specializes in obesity medicine to explore all available options
Cost Comparison: Brand vs. Compounded vs. Alternatives
One of the biggest factors driving interest in compounded semaglutide was cost. Here is how the current options compare:
| Option | Approx. Monthly Cost | Insurance | Notes |
|---|---|---|---|
| Wegovy (injection) | $1,350 retail; $25–$200 with insurance | Varies by plan | Savings card available |
| Ozempic | $900–$1,000 retail; $25–$150 with insurance | Better for diabetes | Savings programs available |
| Wegovy (oral tablet) | $1,000–$1,400 retail | Coverage expanding | New in 2026 |
| Compounded (if legal) | $200–$500 | Rarely covered | Narrow circumstances only |
| Zepbound (tirzepatide) | $1,060 retail | Varies by plan | Eli Lilly savings programs |
| Saxenda (liraglutide) | $1,300 retail; $25 with savings card | Moderate coverage | Daily injection; older GLP-1 |
| Lifestyle programs | $50–$300 | Often partially covered | Dietitian, gym, behavioral therapy |
Important note on Medicare: As of 2026, Medicare Part D has begun covering GLP-1 medications for weight management under the Inflation Reduction Act provisions, though coverage details and formulary placement vary by plan.
Tips for Reducing Costs
- Manufacturer savings programs — Both Novo Nordisk and Eli Lilly offer substantial savings cards for commercially insured patients
- Patient assistance programs — For uninsured or underinsured patients, manufacturer-sponsored programs may provide medications at reduced cost or free
- Novo Nordisk self-pay pricing — Promotional self-pay pricing starting at $199/month for the lowest doses for new patients
- Appeal denied insurance claims — Work with your prescribing physician to submit a prior authorization appeal with clinical documentation
- Explore all formulary options — Your insurer may cover one GLP-1 medication but not another
Safety Considerations
The safety discussion around compounded semaglutide is not theoretical. Real harm has occurred, and understanding the risks is essential for making informed decisions.
Risks of Unregulated or Non-Compliant Sources
The FDA received 605 adverse event reports linked to compounded semaglutide products as of July 2025. The most common issues included:
Dosing errors: Many compounded products used non-standard concentration labeling, leading patients to accidentally inject 5 to 20 times their intended dose. Unlike the pre-filled Ozempic and Wegovy pens (which deliver a fixed dose with each click), compounded semaglutide typically came in multi-dose vials that required patients to draw up their own doses using syringes—a process that leaves significant room for error.
Sterility failures: FDA inspections of multiple compounding facilities uncovered serious manufacturing violations, including the use of non-sterile ingredients for injectable products, inadequate contamination controls, and the release of products that failed sterility and potency testing.
Counterfeit products: The FDA has identified fraudulent compounded semaglutide products with false label information, including labels listing compounding pharmacies that do not exist.
Ingredient concerns: Most compounded semaglutide used semaglutide salt forms (sodium or acetate) rather than the base form used in the FDA-approved products. These salt forms have not undergone the same rigorous testing and may not be equivalent in terms of safety, efficacy, or pharmacokinetics.
Side Effects of Semaglutide (All Forms)
Even with the FDA-approved products, semaglutide carries a well-characterized side effect profile. Clinical trial data from the STEP program has documented the following (Wilding et al., 2021):
Common gastrointestinal effects (reported in clinical trials):
- Nausea (approximately 44% vs. 16% with placebo)
- Diarrhea (approximately 30% vs. 16% with placebo)
- Vomiting (approximately 25% vs. 6% with placebo)
- Constipation
- Abdominal discomfort
Important context: Research indicates that the vast majority (99.5%) of gastrointestinal adverse events in clinical trials were non-serious, and 98.1% were mild to moderate in severity. These effects were most common during the dose-escalation phase and tended to diminish over time (Wharton et al., 2022).
Boxed warning: Semaglutide carries an FDA boxed warning regarding thyroid C-cell tumors based on animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
The Importance of Medical Supervision
Regardless of how you access semaglutide, medical supervision is essential. A qualified healthcare provider can evaluate whether semaglutide is appropriate, monitor for side effects, screen for contraindications, manage the dose-escalation schedule, and coordinate with other medications.
Learn more about peptide safety: Peptide Side Effects: What to Know Before You Start
Frequently Asked Questions
Is compounded semaglutide still available in 2026?
In very limited circumstances, yes. Compounding pharmacies may still prepare semaglutide for individual patients when a licensed prescriber documents a specific medical need that cannot be met by the commercially available products. However, the broad, low-cost compounded semaglutide that was widely available during the shortage is no longer legally produced.
Did the FDA “ban” compounded semaglutide?
Not exactly. The FDA did not issue a blanket ban on all semaglutide compounding. What happened is that the legal basis for compounding copies of FDA-approved semaglutide products (the drug shortage exception) ceased to exist when the shortage was resolved in February 2025. The FDA has enforced this existing rule, but has also acknowledged that legitimate, patient-specific compounding may continue in appropriate circumstances.
Why was compounded semaglutide so much cheaper?
Compounding pharmacies did not bear the costs of clinical trials, the FDA approval process, or the extensive manufacturing quality systems required of pharmaceutical companies. They also sourced the active pharmaceutical ingredient from third-party suppliers at much lower cost.
Can my doctor still prescribe compounded semaglutide?
A prescriber can write a prescription for compounded semaglutide if they determine there is a legitimate, patient-specific medical need that cannot be met by the commercially available product. However, the prescription cannot simply be for the purpose of obtaining a cheaper version of an FDA-approved drug. In practice, finding a compliant pharmacy has become significantly more difficult.
What is the difference between semaglutide sodium and semaglutide base?
FDA-approved Ozempic and Wegovy use semaglutide in its base form. Many compounding pharmacies used semaglutide sodium or semaglutide acetate—salt forms of the molecule. While these contain the same core peptide, salt forms can differ in stability, potency, and how the body absorbs and processes them. The FDA has raised concerns that these salt forms have not been adequately tested.
Are there any generic versions of semaglutide?
As of early 2026, there are no FDA-approved generic versions of semaglutide. Novo Nordisk holds patents that are expected to provide market exclusivity for several more years. When patents eventually expire, biosimilar versions may become available, but that timeline remains uncertain.
What should I do if I am currently using compounded semaglutide?
Consult with your prescribing healthcare provider as soon as possible. They can help you transition to an FDA-approved product, evaluate your insurance coverage options, and ensure continuity of your treatment. Do not abruptly stop treatment without medical guidance.
How effective is semaglutide for weight loss based on clinical evidence?
The landmark STEP 1 trial demonstrated that participants receiving semaglutide 2.4 mg weekly plus lifestyle intervention achieved an average weight reduction of 14.9% from baseline over 68 weeks, compared to 2.4% with placebo. Additionally, 86% of participants achieved at least 5% weight loss (Wilding et al., 2021).
Key Takeaways
- The semaglutide shortage is over. The FDA resolved the shortage in February 2025, and Novo Nordisk has invested billions in manufacturing expansion to meet demand.
- Most compounded semaglutide is no longer legal. Once the shortage ended, compounding pharmacies lost the legal authority to produce copies of FDA-approved semaglutide, with narrow exceptions.
- The FDA has actively enforced. Over 50 warning letters were sent to compounders and manufacturers in September 2025.
- Brand-name options are more accessible. Ozempic, Wegovy (injection and new oral tablet), and competing GLP-1 medications are all widely available in 2026.
- Cost remains a barrier for many. While savings programs and expanding insurance coverage help, retail prices of FDA-approved GLP-1 medications remain high for uninsured patients.
- Safety concerns with compounded products were real. Over 600 adverse event reports, dosing errors, sterility failures, and counterfeit products underscored the risks.
- Medical supervision is essential. Whether using FDA-approved or any other approach, working with a qualified healthcare provider is critical.
- The GLP-1 landscape continues to evolve. New medications, oral formulations, and expanding insurance coverage are making legitimate options more accessible every year.
Related Articles
- What Are Peptides? A Complete Beginner’s Guide — Foundational overview of peptide science.
- Best Peptides for Weight Loss in 2026: Evidence-Based Guide
- Semaglutide for Weight Loss: Results, Dosage & What to Expect
- Tirzepatide for Weight Loss: Dosage, Results & What to Know
- Are Peptides Legal? 2026 Regulatory Guide
- Peptide Side Effects: What to Know Before You Start
Legal Disclaimer: This article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or supplement regimen.
Peptide+ does not sell, distribute, or recommend any specific compounded medications. Nothing in this article should be interpreted as an endorsement of compounded semaglutide or any non-FDA-approved product. All treatment decisions should be made in consultation with a licensed healthcare provider.
Article #19 in the Peptide+ Content Series. Last updated: March 2026.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(1):94-105. PMC
- Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK. Spotlight on the Mechanism of Action of Semaglutide. Curr Issues Mol Biol. 2024;46(12):14001-14029. PMC
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2022;325(14):1414-1425. PMC
- Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5-13. PubMed
- Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide for the treatment of overweight and obesity: A review. Mol Biol Rep. 2023;50(1):885-899. PMC
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2025. FDA.gov
- U.S. FBI Internet Crime Complaint Center. Safety Concerns Related to Fraudulent Compounding Practices Associated with Weight Loss Drugs. 2025. IC3.gov